Clinical Trials at Providence Portland Medical Center
As of June 2026, 128 paid clinical trials are recruiting at Providence Portland Medical Center, located at 5050 NE HOYT ST, SUITE 155, PORTLAND, OR 97213-2991, phone (503) 215-6819 in Portland, Oregon. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Breast Cancer and Endometrial Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
128 clinical trials at Providence Portland Medical Center
·Clear filters·↓ Download CSVStudying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
About research studies in Portland
Portland has approximately 1,082 recruiting research studies across a wide range of therapeutic areas. Oregon hosts a diverse network of universities, academic medical centers, and community hospitals that run clinical trials across oncology, cardiology, neurology, and many other therapeutic areas.
Common conditions studied in Portland
- Acute Myeloid Leukemia (20 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Breast Cancer (20 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Endometrial Cancer (19 active studies). Recruiting Endometrial Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Heart Failure (17 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Ovarian Cancer (15 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Advanced Solid Tumor (14 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Portland
- Oregon Health and Science University
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
- AstraZeneca
- SWOG Cancer Research Network
Local regulations and guidelines
Clinical trials in Oregon are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Oregon research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Portland. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Portland
Hipa.ai aggregates every recruiting study in Portland from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Portland?
There are approximately 1,082 recruiting clinical trials in Portland, Oregon listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Portland pay participants?
Most recruiting trials in Portland compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Portland?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Portland?
The most common conditions under active study in Portland include Acute Myeloid Leukemia (20), Breast Cancer (20), Endometrial Cancer (19), Heart Failure (17), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Portland?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Portland on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Portland?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Portland?
Recruiting research sites in Portland include Oregon Health and Science University, Oregon Health & Science University, Providence Portland Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Portland right now?
The largest active categories in Portland are Cancer & tumors (391), Neurology & pain (67), Cardiovascular (47). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Providence Portland Medical Center?
Providence Portland Medical Center is located at 5050 NE HOYT ST, SUITE 155, PORTLAND, OR 97213-2991. Use the Google Maps link in the intro above to get directions.
How do I contact Providence Portland Medical Center?
You can reach Providence Portland Medical Center by phone at (503) 215-6819. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.